Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.

ABSTRACT: In individuals with multiple sclerosis, physical and cognitive disability progression are clinical and pathophysiological hallmarks of the disease. Despite shortcomings, particularly in capturing cognitive deficits, the Expanded Disability Status Scale is the assessment of disability progression most widely used in clinical trials. Here, we review treatment effects on disability that have been reported in large clinical trials of disease-modifying treatment, both among patients with relapsing-remitting disease and among those with progressive disease. However, direct comparisons are confounded to some degree by the lack of consistency in assessment of disability progression across trials. Confirmed disability progression (CDP) is a more robust measure when performed over a 6-month than a 3

SUBMITTER: Wiendl H 

PROVIDER: S-EPMC4464731 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature